Effectiveness and safety of trifluridine/tipiracil in patients with metastatic colorectal cancer in clinical practice in Poland

被引：0

作者：

Radecka, B. ^{[1
]}

Gelej, M. ^{[2
]}

Streb, J. ^{[3
]}

Siedlaczek, A. ^{[4
]}

Kryka, K. ^{[3
]}

Tokajuk, P. ^{[5
]}

Winsko-Szczesnowicz, K. ^{[5
]}

Czernek, U. ^{[6
]}

Sobczak, M. ^{[7
]}

Malik, M. ^{[8
]}

Bodnar, L. ^{[9
]}

Foszczynska-Kloda, M. ^{[10
]}

Hetman, K. ^{[10
]}

Skiewicz, M. Welnicka-Ja ^{[11
]}

Wierzbicka, K. ^{[11
]}

Orlikowska, M. ^{[12
]}

Becht, R. ^{[13
]}

Deptala, A. ^{[14
]}

Itrych, B. ^{[15
]}

Kania-Zembaczynska, B. ^{[16
]}

机构：

[1] Univ Opole, Inst Med Sci, Dept Oncol, Opole, Poland

[2] Tadeusz Koszarowski Reg Canc Ctr, Dept Clin Oncol, Opole, Poland

[3] Jagiellonian Univ Hosp Krakow, Krakow, Poland

[4] Univ Opole, Inst Math & Comp Sci, Opole, Poland

[5] Comprehens Canc Ctr Bialystok, Med Oncol Dept, Bialystok, Poland

[6] Med Univ Lodz, Copernicus Mem Hosp Lodz, Dept Chemotherapy, Lodz, Poland

[7] Copernicus Mem Hosp Lodz, Lodz, Poland

[8] Lower Silesian Oncol Ctr, Clin Oncol Dept, Wroclaw, Poland

[9] Warmia & Mazury Oncol Ctr, MSWiA Hosp, Oncol & Immunooncol Clin, Olsztyn, Poland

[10] West Pomeranian Oncol Ctr Szczecin, Szczecin, Poland

[11] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland

[12] Kociewie Hlth Ctr Starogard Gdanski, Oncol Dept, Starogard Gdanski, Poland

[13] Pomeranian Med Univ, Clin Dept Oncol Chemotherapy & Canc Immunotherapy, Szczecin, Poland

[14] Med Univ Warsaw, Cent Clin Hosp MSWiA, Clin Oncol & Hematol, Warsaw, Poland

[15] Cent Clin Hosp MSWiA, Clin Oncol & Breast Dis, Ctr Postgrad Med Educ, Warsaw, Poland

[16] Beskidian Oncol Ctr Bielsko Biala, Dept Oncol & Oncohematol, Bielsko Biala, Poland

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.04.139

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-57

引用

页码：S108 / S108

页数：1

共 50 条

[41] Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
Garcia-Alfonso, Pilar
Munoz, Andres
Jimenez-Castro, Jeronimo
Jimenez-Fonseca, Paula
Pericay, Carles
Longo-Munoz, Federico
Reyna-Fortes, Carmen
Argiles-Martinez, Guillem
Gonzalez-Astorga, Beatriz
Jose Gomez-Reina, Maria
Ruiz-Casado, Ana
Rodriguez-Salas, Nuria
Lopez-Lopez, Rafael
Carmona-Bayonas, Alberto
Conde-Herrero, Veronica
Aranda, Enrique
CANCERS, 2021, 13 (18)
[42] The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting
Shibutani, Masatsune
En, Wang
Okazaki, Yuki
Kashiwagi, Shinichiro
Fukuoka, Tatsunari
Iseki, Yasuhito
Hirakawa, Kosei
Ohira, Masaichi
ANTICANCER RESEARCH, 2021, 41 (12) : 6211 - 6216
[43] Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales
Bullement, Ash
Underhill, Stuart
Fougeray, Ronan
Hatswell, Anthony James
CLINICAL COLORECTAL CANCER, 2018, 17 (01) : E143 - E151
[44] Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada
Samawi, H. H.
Brezden-Masley, C.
Afzal, A. R.
Cheung, W. Y.
Dolley, A.
CURRENT ONCOLOGY, 2019, 26 (05) : 319 - +
[45] Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status
C. Carriles
P. Jimenez-Fonseca
M. Sánchez-Cánovas
P. Pimentel
A. Carmona-Bayonas
T. García
M. Carbajales-Álvarez
A. Lozano-Blázquez
Clinical and Translational Oncology, 2019, 21 : 1781 - 1785
[46] Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status
Carriles, C.
Jimenez-Fonseca, P.
Sanchez-Canovas, M.
Pimentel, P.
Carmona-Bayonas, A.
Garcia, T.
Carbajales-Alvarez, M.
Lozano-Blazquez, A.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (12): : 1781 - 1785
[47] Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
Sunakawa, Yu
Izawa, Naoki
Mizukami, Takuro
Horie, Yoshiki
Hirakawa, Mami
Arai, Hiroyuki
Ogura, Takashi
Tsuda, Takashi
Nakajima, Takako Eguchi
ONCOTARGETS AND THERAPY, 2017, 10 : 4599 - 4605
[48] Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
Takahashi, Toshiaki
Shigeyasu, Kunitoshi
Kondo, Yoshitaka
Takeda, Sho
Umeda, Hibiki
Moriwake, Kazuya
Kayano, Masashi
Sakurai, Yuya
Nakamura, Shunsuke
Takahashi, Masafumi
Nitta, Kaori
Yoshida, Kazuhiro
Matsumi, Yuki
Michiue, Hiroyuki
Yamamoto, Hideki
Kishimoto, Hiroyuki
Teraishi, Fuminori
Shoji, Ryohei
Kanaya, Nobuhiko
Kashima, Hajime
Kakiuchi, Yoshihiko
Kuroda, Shinji
Kagawa, Shunsuke
Fujiwara, Toshiyoshi
BMC CANCER, 2025, 25 (01)
[49] Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer
Yoshino, Takayuki
Uetake, Hiroyuki
Funato, Yuya
Yamaguchi, Yasunobu
Koyama, Takahiko
Ozawa, Daisuke
Tajiri, Masaru
Muro, Kei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (05) : 700 - 706
[50] RAS mutation specific survival in patients with metastatic colorectal cancer treated with trifluridine/tipiracil
Grell, Peter
Batko, Stanislav
Pirsthuk, Alina
Borilova, Simona
Polachova, Katerina
Mazuchova, Blanka
Tomasek, Jiri
Fabian, Pavel
Berkovcova, Jitka
Bardelcik, Miroslav
Obermannova, Radka
Buchler, Tomas
Kiss, Igor
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL)

← 1 2 3 4 5 →